Previous Close | 2.0300 |
Open | 2.0300 |
Bid | 0.6000 |
Ask | 2.8500 |
Strike | 5.00 |
Expire Date | 2024-12-20 |
Day's Range | 2.0300 - 2.0300 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
Kodiak (KOD) reports better-than-expected first-quarter 2024 results and provides updates regarding its pipeline development plans.
Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended March 31, 2024.
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that the first patients with diabetic retinopathy (DR) have been treated in the randomized double masked Phase 3 GLOW2 study of tarcocimab tedromer.